

Expanding the Utilization of Rectal Spacer Hydrogel for Larger Prostate Glands (>80cc): Feasibility and Dosimetric Outcomes

Marcio Fagundes, MD; Maria Amelia Rodrigues, MD; Steve Olszewski, MD; Fazal Khan, CMD; Craig McKenzie, CMD; Alonso Gutierrez, PhD; Michael Chuong, MD; Minesh Mehta, MD

Radiation Oncology Department, Miami Cancer Institute, Miami, Florida

Limitations of this report include:

- Study was retrospective in nature
- The SpaceOAR Hydrogel pivotal study did not evaluate glands >80cc so the results may not be comparable
- This study was not designed or powered to make definitive claims about the benefits of a spacer
- These results may not be achieved with other large gland protocols
- The pivotal study done for SpaceOAR Hydrogel utilized fractionation schedules of 79.2Gy over 44 fractions

"Hydrogel placement is feasible in large glands >80cc, even when including a subgroup of patients with prostates >100cc (100.1-186.6 cc) with very favorable dosimetric outcomes which are in line with benchmark published results with smaller glands."

78Gy over 39 fractions was not the method used in the SpaceOAR™ Hydrogel single-blind Phase III trial performed to evaluate dosimetric and clinical effects of SpaceOAR Hydrogel. IG-IMRT delivered at 79.2 Gy in 1.8-Gy fractions was the method used.

Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.

The content of this article/publication is under the sole responsibility of its author/publisher and does not represent the opinion of BSC.

CAUTION: US Federal law restricts this device to sale by or on the order of a physician.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device.

Information for use only in countries with applicable health authority registrations. This material not intended for use in France.

Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. Please check availability with your local sales representative or customer service.

All trademarks are the property of their respective owners.

© 2021 Boston Scientific Corporation or its affiliates. All rights reserved. URO-1141303-AA DEC 2021

33 patients with localized prostate cancer with glands exceeding 80cc were treated at a single institution using intensity-modulated radiotherapy (IMRT, n=15) and proton therapy (n=18) from 2017 to 2019. 16 patients received conventional fractionation and 17 received hypofractionation. Previous prospective multi-institutional studies only included prostates <80cc.¹ The mean separation was 9.9 mm (range, 6.6 - 19.4 mm) for glands measuring >80 to 100 cm³ and 8.8 mm (range, 4.7 - 12.3 mm) for glands >100 cm³. Patients were assessed weekly using common terminology criteria for adverse events (CTCAE).


Dosimetric outcomes

		Conventional fractionation (78 Gy/39 fractions)			
	Pts	rV75	rV70	rV60	rV50
All	16	0.84% (0-2.7)	2.25% (0-4.7)	5.61% (1.7-9.5)	10.5% (2.39-15.2)
P + SV	4	0.75% (0.06-1.77)	2% (0.75-4.4)	5.47% (2.5-9.5)	10.1% (6.4-15.2)
P + SV + Lns	12	0.87% (0-2.7%)	2.3% (0-4.7)	5.66% (1.7-8.9)	10.7% (2.3-14.9)
P + SV (IMRT)	2	0.58% (0.06-1.1)	1.61% (0.93-2.3)	4.95% (4.5-5.4)	9.45% (9.4-9.5)
P + SV (PT)	2	0.93% (0.09-1.77)	2.57% (0.75-4.4)	6% (2.5-9.5)	10.8% (6.4-15.2)

		Moderate hypofractionation (70 Gy/28 fractions)			
	Pts	rV65	rV63	rV60	rV50
All P + SV	17	1.67% (0-5.8)	2.3% (0.1-6.7)	3.4% (0.4-9.6)	8.6% (3.3-15.7)
P + SV (IMRT)	9	1.16% (0-4.6)	1.65% (0.1-5.8)	2.5% (0.3-7.8)	6.9% (2.46-15)
P + SV (PT)	8	2.24% (0.7-5.8)	3.1% (1.3-6.7)	4.48% (2.4-9.6)	10.5% (4.9-15.7)


Abbreviations: IMRT = intensity modulated radiation therapy; (P + SV) = prostate plus seminal vesicles; (P + SV + Lns) = prostate plus seminal vesicles plus lymph nodes; PT = proton therapy; Pts = patients.

Conventional fractionation (78 Gy/39 fractions) All patients (n=16)



Mean value and range, rV75 = 0.84% (range, 0 - 2.7), rV70 = 2.25% (range, 0 - 4.7), rV60 = 5.61% (range, 1.7 - 9.5), rV50 = 10.5% (range, 2.39 - 15.2)

Moderate hypofractionation (70 Gy/28 fractions) All P + SV (n=17)



Mean value and range, rV65 = 1.67% (range, 0 - 5.8), rV63 = 2.3% (range, 0.1 - 6.7), rV60 = 3.4% (range = 0.4 - 9.6), rV50 = 8.6% (range, 3.3 - 15.7)

Link to full article:

[https://www.advancesradonc.org/article/S2452-1094\(21\)00009-9/fulltext](https://www.advancesradonc.org/article/S2452-1094(21)00009-9/fulltext)

1. Mariados N, Sylvester J, Shah D, et al. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. *Int J Radiat Oncol Biol Phys.* 2015;92(5):971-977.